Clinical Trials

21 results for Bladder Cancer


Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

  • Condition: Healthy Control, Localized Urothelial Carcinoma of the Renal Pelvis and Ureter, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bl
  • Intervention: Other: Cytology Specimen Collection Procedure, Other: Laboratory Biomarker Analysis
  • Study ID: NCT01050504
View Trial

Familial and Atypical Urothelial Cancer Registry

  • Condition: Urothelial Cancer, Renal Pelvis Cancer, Ureter Cancer, Bladder Cancer
  • Intervention: Other: saliva sample and questionaire, Other: saliva sample, questionaire
  • Study ID: NCT00902590
View Trial

A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer

  • Condition: Urothelial Cancer
  • Intervention: Biological: nivolumab, Biological: ipilimumab, Drug: Gemcitabine, Drug: cisplatin, Drug: carboplatin
  • Study ID: NCT03036098
View Trial

A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGF

  • Condition: Urothelial Cancer
  • Intervention: Drug: JNJ-42756493
  • Study ID: NCT02365597
View Trial

A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Metastatic Urothelial Cancer Refractory to Platinum

  • Condition: Stage IV Bladder Urothelial Carcinoma
  • Intervention: Procedure: Computed Tomography, Other: Laboratory Biomarker Analysis, Biological: Pembrolizumab, Procedure: Positron Emission Tomography, Biological: Recombinant EphB4-HSA Fusion Protein
  • Study ID: NCT02717156
View Trial

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab (MK-3475) Before Cystectomy for Patients With Muscle-invasive Urothelial Bladder Cancer.

  • Condition: Urothelial Bladder Carcinoma
  • Intervention: Drug: Pembrolizumab (MK-3475)
  • Study ID: NCT02736266
View Trial

A Phase 1b Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Immune Checkpoint Inhibitor (CPI) Therapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

  • Condition: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms
  • Intervention: Drug: enfortumab vedotin, Drug: pembrolizumab, Drug: atezolizumab
  • Study ID: NCT03288545
View Trial

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

  • Condition: Urothelial Carcinoma, Renal Cell Carcinoma
  • Intervention: Drug: cabozantinib, Drug: atezolizumab, Drug: cabozantinib
  • Study ID: NCT03170960
View Trial

Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)

  • Condition: Metastatic Urothelial Carcinoma, Bladder Cancer
  • Intervention: Drug: Cabozantinib, Drug: Pembrolizumab
  • Study ID: NCT03534804
View Trial

Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Feasibility Phase II Randomized Clinical Trial ("URANUS")"

  • Condition: Upper Tract Urothelial Carcinoma
  • Intervention: Procedure: RNU, Drug: Gemcitabine/Cisplatin, Drug: M-VAC Protocol
  • Study ID: NCT02969083
View Trial

Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: Sacituzumab govitecan
  • Study ID: NCT03547973
View Trial

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Car

  • Condition: Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
  • Intervention: Drug: Durvalumab, Drug: Tremelimumab, Drug: Cisplatin + Gemcitabine, Drug: Carboplatin + Gemcitabine
  • Study ID: NCT03682068
View Trial

A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL-7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

  • Condition: Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurre
  • Intervention: Drug: Atezolizumab, Biological: Glycosylated Recombinant Human Interleukin-7, Other: Laboratory Biomarker Analysis
  • Study ID: NCT03513952
View Trial

A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

  • Condition: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
  • Intervention: Drug: PRS-343
  • Study ID: NCT03330561
View Trial

Cabozantinib Plus Durvalumab in Patients With Advanced and Chemotherapy-treated Bladder Carcinoma, of Urothelial and Non-urothelial Histology: an Open-label, Single-centre, Phase 2, Single-arm Proof-of-concept Trial: ARCADIA Study

  • Condition: Bladder Carcinoma
  • Intervention: Drug: Cabozantinib, Drug: Durvalumab
  • Study ID: NCT03824691
View Trial

Efficacy and Safety of Neoadjuvant Chemotherapy With Dose Dense MVAC Followed by Radical Surgery in Patients With MIBC and Locally Advanced Urothelial Carcinoma of Bladder: Phase II, Single-arm Study

  • Condition: Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Neoadjuvant Chemotherapy
  • Intervention: Drug: dose dense MVAC with pegylated GCSF
  • Study ID: NCT04047693
View Trial

An Open-label, Dose-escalation, Bi-weekly Phase I+II Clinical Trial in Treating Patients With Locally Advanced and Metastatic Urothelial Carcinoma

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: ZKAB001 5mg/kg, Drug: ZKAB001 10mg/kg, Drug: ZKAB001 15mg/kg
  • Study ID: NCT03676946
View Trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Co

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: Atezolizumab, Drug: Enfortumab Vedotin, Drug: Niraparib, Drug: Hu5F9-G4, Drug: Isatuximab, Drug: Linagliptin, Drug: Tocilizumab
  • Study ID: NCT03869190
View Trial

Phase II Study of Avelumab in Combination With AXL Inhibitor AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: Avelumab, Drug: AVB-S6-500
  • Study ID: NCT04004442
View Trial

A Phase II Study of Intermittent Checkpoint Inhibitor Therapy in Patients With Advanced Urothelial Carcinoma

  • Condition: Urothelial Carcinoma
  • Intervention: Drug: Pembrolizumab, Drug: Atezolizumab, Drug: Durvalumab, Drug: Nivolumab, Drug: Avelumab
  • Study ID: NCT04322643
View Trial

Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy

  • Condition: Bladder Cancer, Bladder Cancer, Metastatic
  • Intervention: Drug: Atezolizumab
  • Study ID: NCT04138628
View Trial